Gene Therapy and CRISPR: Is 2026 the Year We Finally "Fixed" Hereditary Diseases?
In 2026, the Human Genetics Market is celebrating a major milestone: the first wave of FDA-approved CRISPR gene therapies for common conditions like sickle cell anemia and certain forms of inherited blindness. This "molecular surgery" is no longer an experimental dream; it is a life-saving reality for thousands of patients. The China Human Genetics Market is particularly aggressive in this...
0 Σχόλια 0 Μοιράστηκε 5 Views 0 Προεπισκόπηση